Memory Maintenance

Dear Dr. Dean,

I will be 73 in May. Last week, I was diagnosed with early signs of Alzheimer’s disease.

Briefly: I’ve had 6 spinal surgeries from late 2000—April 2012. Two at Marin General; the rest at UCSF. They began fusing my spine at the 2nd surgery.

In 2006 I had surgery that fused my back from thoracic to tail bone. I went from surgery to ICU recovery, but remained in an 8-day coma. My family said I was a little “slow” for several months post-surgery; the doctors called it Dementia.

In April, 2012, I had a major reconstruction, replacing hardware, etc. I was now fused from my cervical all the way down to my tailbone. After the 2-3-month recovery, I found myself in a constant brain fog (San Francisco style), poor sleep, and pain still in my feet. Also, my right leg appeared to be shorter and my gait was like a drunken sailor (no offense).

I have been a longtime customer of yours (I live in Novato) and have always been interested in anti-aging and enhancing/improving my cognition. I take many of your products, Whole Turmeric Power, Memory Upgrade, Turbo Blast, Taurine & More, and Fold Right occasionally. Life-Enhancement is my main source for both supplementation and related science.

Because of my constant brain fog, I began taking your GalantaMind back in October, 2015. I now take GalantaMind w/Ginkgo.

I first went through testing at UCSF’s Memory & Aging Center, in 2014. At a follow-up, the doctor said he thought my supplements may be the “cognition villains,” and wanted to show my vitamin/supplement list to a pharmacist who “knew about alternate supplementation”.

This wasn’t the first time I knew more than a doctor regarding supplementation. I didn’t return for a few months. In the mean-time, I did UCSF’s Sleep Study. ”No apnea, but need to get more sleep”.

Getting to my point: Seemingly suddenly and ever since my 2012 surgery, I have been in a constant brain fog, constant fatigue. I knew I didn’t suddenly get old instantly. Finally, UCSF’s Memory & Aging Unit sent me to Lawrence-Berkeley under Clinical Trials. I had PET scans, and more testing back at UCSF, including an MRI.

Followup diagnosis on Feb. 2, 2016: Early stages of Alzheimer’s disease. In order to qualify for further clinical trials, I was given an Rx for Razadyne (Galantamine ER, 16 mg). To me, it looked exactly like the GalantaMind I have been taking, except for the extended release. Of course there are no synergistic co-factors as in your product, so I’m taking an inferior Rx. The doctor told me to discontinue taking GalantaMind. Besides, he said, Razadyne will most likely be cheaper. (It isn’t, even though the co-factors aren’t present.)

However, since I began your GalantaMind my long-term memory has amazed family and friends. I just have problems with the “here and now,” or executive functions. It takes me a while, with effort, to do/process things.

Is there a difference between your GalantaMind and the Rx Razadyne?

I think I was told to only take Razadyne because the makers of Razadyne pay for clinical trials, and they want a “pure landscape” unfettered with “supplements with uncertain purity.”

OK, I can take Razadyne, but I will take another product with choline, B6, plus DMAE, vinpocetine, etc. So what’s the difference?

Anyway, I appreciate your continuing articles on Alzheimer’s and cognition in general. Thanks to Will Block and Pearson & Shaw.

Any insight would be appreciated. This is for my info only. You will not be interfering, or contradicting a physician’s “opinion.” Thanks for listening.

JOE, Novato, CA

Hi Joe,

Thanks for the detailed report. Sorry to hear about your condition, but I think you’re going about this in the right way. I don’t believe there’s a qualitative difference between the galantamine in LE’s GalantaMind or the pharmaceutical version, Razadyne. I believe you are proceeding appropriately by taking the additional co-factors.

Also, I think your use of DMAE1 and Vinpocetine2 is appropriate.

Unfortunately, there is no “silver bullet” yet for Alzheimer’s. I agree with those who believe we must use multi-pronged approaches for the best outcome.3,4 I suggest you consider adding phosphatidylserine5 (300 mg/day) and acetyl-L-carnitine6 (1,500 mg/day) to your regimen.

In addition, you might consider methylene blue. Methylene blue is the world’s oldest synthetic drug. It was created in 1876, and has been used to treat a variety of clinical conditions, including malaria and urinary tract infections, and is used commercially today as a fish tank cleaner/antiseptic.7

Recently, methylene blue has been found to be an effective inhibitor of abnormal tau proteins in the brain, which are involved with the pathogenesis of Alzheimer’s disease. and it is currently undergoing trials as an anti-Alzheimer’s drug.8 Doses found to be effective for cognitive enhancing purposes are in the range of 50-150 mg/day. The only side effect of note is blue urine—so I advise my patients on methylene blue therapy to stock up on blue underwear.

Improvement in the Short Term Memory test of the Scale of Clinical Assessment for Geriatrics (SCAG) in 200 Alzheimer’s patients treated with deprenyl for 120 days, compared to placebo. Deprenyl users scored dramatic improvements.
LEM1603graph274.jpg
(click on thumbnail for full sized image)

Deprenyl—also known as selegiline is a monoamine oxidase B inhibitor, that has found wide use as an anti-Parkinsonian drug, anti-depressant, and despite controversy, has been used beneficially by many sufferers of Alzheimer’s disease.9 Deprenyl is neuroprotective, increases the lifespan of several species, and generally improves cognitive function and behavioral disabilities in Alzheimer’s patients, although it unfortunately does not seem to slow the progress of the disease. Doses of 5 mg twice/day have been most commonly used in Alzheimer’s studies, but lower doses may be effective as well. Prof. Josef Knoll, the developer and leading proponent of deprenyl has taken just one mg of deprenyl per day for many years, and he is a still-practicing scientist in his 90s.10

Please keep us apprised of how you’re doing.

Ward Dean, MD

References

  1. Ferris SH, Sathananthan G, Gershon S, Clark C. Senile dementia: treatment with deanol. J Am Geriatr Soc. 1977 Jun;25(6):241-4.
  2. Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618-28.
  3. Schmitt B, Bernhardt T, Moeller HJ, Heuser I, and Frolich L. Combination therapy in Alzheimer’s Disease: A review of current evidence. CNS Drugs. 2004; 18(3) 827-844.
  4. Zheng H, Fridkin M, and Youdim M. From single target to multitarget/network therapeutics in Alzheimer’s therapy. Pharmaceuticals. (Basel). 2014 Feb; 7(2): 113-135.
  5. Zhang YY, Yang LQ, Guo LM. Effect of phosphatidylserine on memory in patients and rats with Alzheimer's disease. Genet Mol Res. 2015 Aug 10;14(3):9325-33.
  6. Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res. 1994;20(4):169-76.
  7. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. “Lest we forget you—methylene blue. . .” Neurobiol Aging. 2011 Dec;32(12):2325.
  8. Lin AL, Poteet E, Du F. Methylene Blue as a cerebral metabolic and hemodynamic enhancer. PLoS One. 2012; 7(10): e46585.
  9. Raffaele R, Rampello L, Veccio I, Giammona G, Malaguarnera M, Nicoletti G, Ruggieri M, and Nicoletti F. The use of selegiline in the treatment of cognitive deficits in elderly patients. Arch Gerontol Geriatr. Suppl. 8 (2002) 319-326.
  10. Knoll, Joseph (2012-10-12). How Selegiline ((-)-Deprenyl) slows brain aging. Bentham Science Publishers. Kindle Edition.

Featured Product

  • Learn more about Galantamine benefits and implementation strategies.

Ingredients in this Article

FREE Subscription

  • You're just getting started! We have published thousands of scientific health articles. Stay updated and maintain your health.

    It's free to your e-mail inbox and you can unsubscribe at any time.
    Loading Indicator